MEDRAD Mark 7 Arterion Injection System

K193028 · Bayer Medical Care, Inc. · DXT · Dec 5, 2019 · Cardiovascular

Device Facts

• Record ID: K193028
• Device Name: MEDRAD Mark 7 Arterion Injection System
• Applicant: Bayer Medical Care, Inc.
• Product Code: DXT · Cardiovascular
• Decision Date: Dec 5, 2019
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.1650
• Device Class: Class 2

Intended Use

The MEDRAD® Mark 7 Arterion Injection System is indicated to be used specifically for the purposes of injecting contrast medium and common flushing solutions into humans for angiographic studies. The ISI option is indicated for the specific purpose of allowing a MEDRAD® Mark 7 Arterion Injection System to interface with an angiography imaging system.

Device Story

Software-controlled automated injection system; uses 150 ml disposable syringe to deliver contrast medium and flushing solutions. User programs volume, flow rate, and pressure limits via LCD touch screen. System features include syringe heat maintainer, multi-phase protocol memory, and manual/foot switch controls. Used in clinical settings for angiographic procedures. ISI module enables interface with angiography imaging systems to synchronize injection and imaging. Output is controlled delivery of contrast; assists clinicians in performing diagnostic angiographic studies.

Clinical Evidence

No clinical data. Bench testing from previous 510(k) submissions remains applicable; no new verification testing required for administrative update.

Technological Characteristics

Software-controlled angiographic injector; 150 ml disposable syringe; color LCD touch screen interface; syringe heat maintainer (35°C ± 5°C); pressure limit 100-1200 psi; flow rate 0.1-45.0 ml/sec. Connectivity includes Imaging System Interface (ISI) for angiography system integration. Class II device.

Indications for Use

Indicated for humans undergoing angiographic studies requiring injection of contrast medium and flushing solutions. Includes use of Imaging System Interface (ISI) for interfacing with angiography imaging systems.

Regulatory Classification

Special Controls

*Classification.* Class II (special controls). The device, when it is a non-patient contacting balloon inflation syringe intended only to inflate/deflate balloon catheters and monitor pressure within the balloon, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

Predicate Devices

• MEDRAD Mark 7 Arterion Injection System (K132928)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

December 5, 2019 Bayer Medical Care Inc. Kelly Frank Project Manager 1 Bayer Drive Indianola, Pennsylvania 15051

Re: K193028

Trade/Device Name: MEDRAD Mark 7 Arterion Injection System Regulation Number: 21 CFR 870.1650 Regulation Name: Angiographic Injector And Syringe Regulatory Class: Class II Product Code: DXT Dated: November 4, 2019 Received: November 5, 2019

Dear Kelly Frank:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

For CAPT Alan Stevens Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K193028

Device Name MEDRAD Mark 7 Arterion Injection System

Indications for Use (Describe)

MEDRAD® Mark 7 Arterion Injection System

The MEDRAD® Mark 7 Arterion Injection System is indicated to be used specifically for the purposes of injecting contrast medium and common flushing solutions into humans for angiographic studies.

Imaging System Interface (ISI)

The ISI option is indicated for the specific purpose of allowing a MEDRAD® Mark 7 Arterion Injection System to interface with an angiography imaging system.

Type of Use (Select one or both, as applicable)

| <input checked="true" type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) |
|--------------------------------------------------------------------------------------|
| <input type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) |

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically, with each letter in a bold, sans-serif font. The word is surrounded by a circular design, with the top half of the circle in green and the bottom half in blue. The logo is simple and recognizable, and it is often used to represent the Bayer company.

# 510(k) Summary

| Submitter: | Bayer Medical Care, Inc.<br>1 Bayer Drive<br>Indianola, PA 15051 |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Kelly Frank<br>Project Manager<br>Phone: [phone]<br>Email: [e-mail] |
| Date Prepared: | October 24, 2019 |
| Device Trade Name: | MEDRAD® Mark 7 Arterion Injection<br>System |
| Common Name: | Angiographic Injector and Syringe |
| Classification Name: | Injector and Syringe, Angiographic [21 CFR<br>870.1650] |
| Product Code: | DXT |
| Classification: | Class II |
| Predicate Device: | The subject device is substantially<br>equivalent to the following device:<br>MEDRAD® Mark 7 Arterion Injection<br>System, K132928. |

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically in a bold, sans-serif font. The letters are in a dark blue color. The wordmark is encircled by two curved lines, one in green and the other in blue, forming a ring around the name.

### Device Description:

The MEDRAD Mark 7 Arterion Iniector is a software-controlled medical device used to inject contrast agents from a 150 ml disposable syringe. Commonly referred to as an automated injection system, it is designed to allow a user to fill a disposable syringe and perform an injection with a user programmed volume and flow rate.

#### Indications for Use:

#### MEDRAD Mark 7 Arterion Injection System

The MEDRAD Mark 7 Arterion Injection System is indicated to be used specifically for the purposes of injecting contrast medium and common flushing solutions into humans for angiographic studies.

#### Imaging System Interface (ISI)

The ISI option is indicated for the specific purpose of allowing a MEDRAD Mark 7 Arterion Injection System to interface with an angiography imaging system.

#### Comparison to the Predicate Device:

The modification is an administrative update to include mention of the ISI (Imaging System Interface) module in the Indications for Use for the MEDRAD Mark 7 Arterion Injection System. This update does not involve any changes to the MEDRAD Mark 7 Arterion Injection System Syringe Kit. Table 1 provides a comparison of the proposed MEDRAD Mark 7 Arterion Injection System with the predicate device, the MEDRAD Mark 7 Arterion Injection System cleared per K132928.

The fundamental scientific technology, principle of operation, and intended use are unchanged from the predicate device, the MEDRAD Mark 7 Arterion Injection System cleared per K132928. The differences between the proposed device and the predicate device do not introduce new issues of safety and effectiveness.

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically in a bold, sans-serif font. The letters are a dark blue color. The wordmark is encircled by a ring that is green on the top half and blue on the bottom half.

Table 1. Comparison of MEDRAD Mark 7 Arterion Injection System (proposed device) with predicate device.

| PARAMETER | PREDICATE<br>DEVICE | PROPOSED<br>DEVICE | RATIONALE FOR<br>CHANGE |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| | Mark 7 Arterion<br>Injection System<br>(K132928) | Mark 7 Arterion<br>Injection System | |
| Indications for<br>Use | The MEDRAD Mark 7<br>Arterion Injection<br>System is intended to<br>be used specifically<br>for the purposes of<br>injecting contrast<br>medium and common<br>flushing solutions into<br>humans for<br>angiographic studies. | The MEDRAD Mark<br>7 Arterion Injection<br>System is indicated<br>to be used<br>specifically for the<br>purposes of injecting<br>contrast medium and<br>common flushing<br>solutions into<br>humans for<br>angiographic studies.<br>The ISI option is<br>indicated for the<br>specific purpose of<br>allowing a MEDRAD<br>Mark 7 Arterion<br>Injection System to<br>interface with an<br>angiography imaging<br>system. | Administrative<br>update to add ISI<br>module specific<br>indications for use<br>statement |
| Fill Volume | 1 – 150 ml in 1 ml<br>increments | Same | No change |
| Fill Speed (user) | 1 — 10 ml/sec | Same | No change |
| PARAMETER | PREDICATE<br>DEVICE<br>Mark 7 Arterion<br>Injection System<br>(K132928) | PROPOSED<br>DEVICE<br>Mark 7 Arterion<br>Injection System | RATIONALE FOR<br>CHANGE |
| configurable for<br>AutoFill) | | | |
| Fill Speed<br>(manual control<br>by user) | 1 - 20 ml/sec | Same | No change |
| Fixed Flow Rate | 0.1 to 45.0 ml/sec in<br>0.1 ml increments<br>(Single and Phased<br>protocols)<br>0.1 to 59.9 ml/min in<br>0.1 ml/min<br>increments (ml/m<br>protocol) | Same | No change |
| Variable Flow<br>Rate | 1.0 – 10.0 ml/sec in<br>0.1 ml/sec<br>increments | Same | No change |
| Flow Rate Rise<br>Time | 0.0 to 9.9 seconds in<br>0.1sec increments | Same | No change |
| Delay | 0.0 to 9.9 seconds in<br>0.1sec increments | Same | No change |
| Pressure Limit<br>(150 ml syringe) | 100-1200 psi or 689-<br>8273 kPa in<br>increments of 1 psi<br>(kPa) | Same | No change |
| Syringe Heat<br>Maintainer | 35°C + 5°C | Same | No change |
| Protocol Memory | 40 protocols | Same | No change |
| Injection History | 50 injections | Same | No change |
| PARAMETER | PREDICATE<br>DEVICE<br>Mark 7 Arterion<br>Injection System<br>(K132928) | PROPOSED<br>DEVICE<br>Mark 7 Arterion<br>Injection System | RATIONALE FOR<br>CHANGE |
| Memory | | | |
| Information<br>Display | Color LCD | Same | No change |
| Programming<br>Keys | Software-generated<br>via an LCD touch<br>screen | Same | No change |
| Touch Screen | Yes | Same | No change |
| Multi-Phase | 4 phases per protocol | Same | No change |
| Arming Modes | Single and Multi-<br>arming modes | Same | No change |
| Syringe System | Single (150 ml)<br>syringe | Same | No change |
| Manual Retract<br>Control | Yes | Same | No change |
| Check for Air<br>Control | Yes | Same | No change |
| Variable Flow<br>Option | Yes | Same | No change |
| Hand Switch<br>(start switch) | Yes | Same | No change |
| Foot Switch<br>(start switch) | Yes | Same | No change |
| Variable Flow<br>Hand Controller | Yes | Same | No change |
| Splash Guard | Yes | Same | No change |
| Wiper Seal | Optional | Same | No change |

{6}------------------------------------------------

Image /page/6/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically in a bold, sans-serif font. The letters are arranged in the center of a circle that is divided into two halves. The top half of the circle is green, and the bottom half is blue.

{7}------------------------------------------------

Image /page/7/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically in a bold, sans-serif font. The letters are arranged in the center of a circle that is divided into two halves. The top half of the circle is green, and the bottom half is blue.

{8}------------------------------------------------

Image /page/8/Picture/1 description: The image shows the Bayer company logo. The logo consists of the word "BAYER" stacked vertically, with each letter in a bold, sans-serif font. The word is enclosed in a circular shape, with the top half of the circle being green and the bottom half being blue. The logo is simple and modern, and the colors are bright and eye-catching.

# Performance Data:

Verification testing was not necessary to demonstrate that the modified indication for use remains safe and effective. Performance testing performed with MEDRAD Mark 7 Arterion Injection System which was provided in previous 510(k)s remains applicable.

No performance standards have been established under Section 514 of the Food, Drug and Cosmetic Act for angiographic injectors and syringes.

# Clinical Testing:

No clinical testing was required or performed to support this Special 510(k) Premarket Notification.

## Conclusion:

Bayer Medical Care Inc. considers the MEDRAD Mark 7 Arterion Injection System to be substantially equivalent to the predicate device listed above. The fundamental scientific technology, principle of operation, and intended use are unchanged from the predicate device. The differences between the proposed device and the predicate device do not introduce new issues of safety and effectiveness.